Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 4/20 | 0.43 |
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804790 | 0.86 | KMT2A (0.46) | KMT2A | |
| SCHEMBL6805030 | 0.84 | F2 (0.44) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6808033 | 0.83 | LMNA (0.52) | KMT2AMAPTLMNAGAARORC | |
| SCHEMBL6808403 | 0.77 | TP53 (0.45) | KMT2AMAPTLMNAGAA | |
| SCHEMBL6808849 | 0.75 | BAZ2B (0.42) | — | |
| SCHEMBL6801213 | 0.74 | SMN1; SMN2 (0.54) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL27822593 | 0.71 | CFD (0.83) | CFDKMT2AMAPTLMNAGAA | |
| SCHEMBL4599573 | 0.67 | RAB9A (0.63) | CFDKMT2AMAPTLMNAGAA | |
| SCHEMBL7090663 | 0.67 | PRMT1 (0.58) | F10KMT2AMAPTGAARORC | |
| SCHEMBL6223388 | 0.66 | F10 (0.53) | F10F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | claimed |
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | RCOR3, F2, NCOR2 | CFD 1104/4885F10 64/4885F2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.